Although the clinical criteria are similar in the two studies and between the two arms of each study (disease stage and metastatic sites, previous treatments, median age, performance status, PD-L1 expression), the populations may differ on tumor biological criteria influencing prognosis and treatment efficacy other than PDL1 expression and not reported, such as tumor-infiltrating lymphocytes (TILs) expression or tumor mutation burden (TMB) which may be unbalanced. Here, CD274 is linked to neoplasm.